Shandong Buchang Pharmaceuticals Co Ltd banner

Shandong Buchang Pharmaceuticals Co Ltd
SSE:603858

Watchlist Manager
Shandong Buchang Pharmaceuticals Co Ltd Logo
Shandong Buchang Pharmaceuticals Co Ltd
SSE:603858
Watchlist
Price: 16.28 CNY -1.39% Market Closed
Market Cap: ¥17.2B

EV/FCFF

19
Current
40%
More Expensive
vs 3-y average of 13.6

Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.

EV/FCFF
19
=
Enterprise Value
¥18.9B
/
Free Cash Flow to Firm
¥959.9m

Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.

EV/FCFF
19
=
Enterprise Value
¥18.9B
/
Free Cash Flow to Firm
¥959.9m

Valuation Scenarios

Shandong Buchang Pharmaceuticals Co Ltd is trading above its 3-year average

If EV/FCFF returns to its 3-Year Average (13.6), the stock would be worth ¥11.65 (28% downside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-28%
Maximum Upside
+62%
Average Upside
19%
Scenario EV/FCFF Value Implied Price Upside/Downside
Current Multiple 19 ¥16.28
0%
3-Year Average 13.6 ¥11.65
-28%
5-Year Average 16.9 ¥14.55
-11%
Industry Average 30.7 ¥26.36
+62%
Country Average 28.8 ¥24.73
+52%

Forward EV/FCFF
Today’s price vs future free cash flow to firm

Not enough data available to calculate forward EV/FCFF

Peer Comparison

All Multiples
EV/FCFF
P/E
All Countries
Close
Market Cap EV/FCFF P/E
CN
Shandong Buchang Pharmaceuticals Co Ltd
SSE:603858
17.2B CNY 19 10 326.2
US
Eli Lilly and Co
NYSE:LLY
883B USD 159 44.3
US
Johnson & Johnson
NYSE:JNJ
553.5B USD 29.2 26.1
CH
Roche Holding AG
SIX:ROG
248.4B CHF 26.4 20.1
UK
AstraZeneca PLC
LSE:AZN
209.6B GBP 39.6 27.4
CH
Novartis AG
SIX:NOVN
221.1B CHF 19.6 20.7
US
Merck & Co Inc
NYSE:MRK
270.2B USD 25.1 15.3
IE
Endo International PLC
LSE:0Y5F
244.4B USD 1 486.8 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 45.7 12.1
US
Pfizer Inc
NYSE:PFE
151.8B USD 21.9 19.3
US
Bristol-Myers Squibb Co
NYSE:BMY
122B USD 11.7 16.8
P/E Multiple
Earnings Growth PEG
CN
Shandong Buchang Pharmaceuticals Co Ltd
SSE:603858
Average P/E: 1 052.8
10 326.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
44.3
32%
1.4
US
Johnson & Johnson
NYSE:JNJ
26.1
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
27.4
25%
1.1
CH
Novartis AG
SIX:NOVN
20.7
14%
1.5
US
Merck & Co Inc
NYSE:MRK
15.3
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
12.1
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.3
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.8
16%
1

Market Distribution

In line with most companies in China
Percentile
38th
Based on 4 731 companies
38th percentile
19
Low
0 — 14.5
Typical Range
14.5 — 57
High
57 —
Distribution Statistics
China
Min 0
30th Percentile 14.5
Median 28.8
70th Percentile 57
Max 307 555.7

Shandong Buchang Pharmaceuticals Co Ltd
Glance View

Market Cap
17.2B CNY
Industry
Pharmaceuticals

Shandong Buchang Pharmaceuticals Co Ltd, a stalwart in China's pharmaceutical industry, was founded with a traditional focus but a modern vision. The company thrives on its deep expertise in developing and manufacturing traditional Chinese medicine (TCM) products, capitalizing on the rich tapestry of Eastern medicinal practices. Its extensive portfolio spans cardiovascular, cerebrovascular, and neurological disorders, areas highly pertinent to China’s aging population. By seamlessly integrating modern scientific techniques with age-old herbal wisdom, Buchang positions itself uniquely in a market that appreciates both tradition and innovation. This dual focus allows the company to tap into the growing demand for health solutions that marry efficacy with cultural familiarity. Financially, Buchang Pharmaceuticals' revenue is primarily fueled by its established healthcare products, which are marketed extensively across China’s vast healthcare network. The company shrewdly invests in building dedicated sales channels, leveraging a combination of direct engagement with healthcare professionals and strategic partnerships with medical institutions. Their emphasis on R&D ensures a steady pipeline of products, aiming to break into new therapeutic areas and expand its market presence. Buchang’s strategy to blend traditional remedies with modern delivery forms not only bolsters its domestic sales but also paves the way for potential international expansion, as global interest in holistic and alternative health solutions continues to grow. This sophisticated operational model underscores Buchang's ability to adapt and prosper amid shifting healthcare paradigms.

Intrinsic Value
17.55 CNY
Undervaluation 7%
Intrinsic Value
Price ¥16.28
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett